Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Distress Tolerance and Benzodiazepine Discontinuation in Opioid Agonist Therapy, Phase 2

NCT04109118 is registered in ClinicalTrials.gov with Boston Medical Center as lead sponsor.

NCT NCT04109118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04109118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Distress Tolerance and Benzodiazepine Discontinuation in Opioid Agonist Therapy, Phase 2
Lead sponsor
Boston Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 18, 2021
Completion date
July 8, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

substance use disorders